Tanoto Foundation, Gates Foundation sign MOU to boost health, nutrition, education in Asia
Both foundations will build on their existing relationship and work together to identify, design and implement joint initiatives in areas such as public health and healthcare delivery; maternal and child nutrition; access to quality education; and strengthening the philanthropic ecosystem and capacity-building in the region.
For a start, the Tanoto Foundation and the Gates Foundation will work on a nutrition partnership in Indonesia, said Hari Menon, director of South and South-east Asia at the Gates Foundation.
Belinda Tanoto, member of the board of trustees at Tanoto Foundation, said: 'In today's rapidly changing world, the challenges we face are complex and interconnected, from widening funding gaps to the rising disparity between rich and poor.'
Each initiative under this partnership will have its own specific agreement, which will outline the objectives, scope, budget, roles and responsibilities of both parties.
'These project-specific agreements will also reflect a shared commitment to the principle of ensuring that innovations, knowledge and solutions developed are affordable and accessible to the communities that need them the most,' said both foundations.
On Monday, the Philanthropy Asia Alliance (PAA) announced the launch of the Health for Human Potential Community, which will be supported by the Tanoto and Gates Foundations, among others, such as Temasek Foundation.
This Community aims to reduce preventable deaths and disease burdens in South-east Asia by rallying funders, practitioners and ecosystem partners to collaborate on projects. It has an initial funding target of US$100 million, which will be committed by the organisations supporting it, as well as PAA.
Tanoto Foundation, founded by Sukanto Tanoto and Tinah Bingei Tanoto, has supported education systems, healthcare innovation and leadership development in Asia since its inception in 1981. Meanwhile, the Gates Foundation, launched in 2000 by Bill Gates and Melinda French Gates, has made global efforts to eradicate diseases, expand financial inclusion and enhance agricultural productivity.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
4 days ago
- Business Times
Neuralink sees US$1 billion of revenue by 2031 in vast expansion
[BOSTON] Elon Musk's brain implant company Neuralink expects to put its chips in 20,000 people a year by 2031, generating at least US$1 billion in annual revenue, in a major ramp-up of its work to treat disease and gain unprecedented access to the human mind, according to documents reviewed by Bloomberg. Within six years, the company also plans to have about five large clinics in operation, with at least three versions of its device available, according to a recent presentation shown to investors. One version, Telepathy, is for enabling communication between the brain and machines; another, Blindsight, is aimed at giving vision to blind people; and a third, Deep, would treat tremors and Parkinson's disease. The financial projections, as well as the company's work in patients with tremors and Parkinson's, have not been previously publicly reported. Representatives for Musk and Neuralink did not immediately respond to a request for comment. The company's stated goals show the enormous scale of Musk's vision for Neuralink and the ambitious timeline on which he seeks to operate. Fewer than 10 people are publicly known to have Neuralink brain devices so far as part of clinical trials, and no patients have them to restore vision or treat Parkinson's. By 2029, the company expects to gain regulatory approval in the US for its Telepathy device, and it hopes to perform 2,000 surgeries a year and generate at least US$100 million in annual revenue, according to the documents. Then by 2030, Neuralink sees the launch of its sight-restoring chip Blindsight, expanding to 10,000 surgeries a year and bringing in over US$500 million. The figures assume 'a conservative reimbursement of US$50k per surgery', the documents show. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Neuralink has raised US$1.3 billion from investors and is now valued at US$9 billion, according to PitchBook. Brain-computer interface companies such as Neuralink have attracted significant attention and investment in recent years for potential medical applications. No devices are approved by US regulators for permanent use in humans, as companies are still working on gathering data on safety and effectiveness. Musk has hit a number of milestones with Neuralink, though he is also known for overstating how quickly he will be able to reach technological achievements. For example, in 2015, Musk said that Tesla cars would be able to drive themselves within three years. He moved the timeline back several times and finally launched Robotaxis for testing last month. As part of clinical trials, paralysed patients have used Neuralink devices to control computers, allowing them to browse the internet, play games, and edit videos. The company has also been testing its vision implant in monkeys. Several other brain implant companies are building and testing devices to stimulate or read data from the brain. No brain-computer interfaces are approved commercially for permanent implantation by the US Food and Drug Administration. BLOOMBERG
Business Times
6 days ago
- Business Times
Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push
[PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay US$1.15 billion upfront with a commitment for potential milestones worth as much as US$450 million, it said in a statement on Tuesday (Jul 22). Chief executive officer Paul Hudson is looking for innovation that fits with Sanofi's existing offerings, and Vicebio's experimental shots are intended to prevent several respiratory illnesses including RSV, the target of its new therapy Beyfortus. The deal is expected to close in the fourth quarter, and won't have a significant impact on Sanofi's financial guidance for the year, the company said. The transaction helps Sanofi get closer to making next-generation vaccines that offer protection against multiple respiratory viruses in a single shot that isn't mRNA – the technology behind the blockbuster Covid-19 immunisations. Vicebio's technology allows quicker development of liquid combination vaccines that can be stored at fridge temperatures, simplifying manufacturing and distribution by eliminating the need for freezing. The company is working on a single shot against RSV and human metapneumovirus, or hMPV, which is in an exploratory early-stage study. Like several rivals, Sanofi is focusing on cutting-edge therapies while divesting older medicines and its consumer-health division. BLOOMBERG
Business Times
6 days ago
- Business Times
AstraZeneca vows to spend US$50 billion on US manufacturing, development
[MUNICH/WASHINGTON] AstraZeneca plans to invest US$50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go towards manufacturing as well as research and development, Astra said in a statement. It includes US$4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said on Monday (Jul 21) at an event in Washington, DC. 'With the completion of this investment, substantially all of AstraZeneca's pharmaceuticals sold at the United States will be produced in the United States,' Hassett said. Astra's announcement comes as European drug companies rush to highlight their significant footprints in the US in hopes of mitigating the impact of any potential tariffs from US President Donald Trump. Astra already announced plans in November, a week after Trump's election, to invest US$3.5 billion in the US by the end of 2026, noting at the time that it employs nearly 18,000 people in the country. Since then, European competitors have touted even larger spending plans. Switzerland's Novartis in April announced plans for US$23 billion in US-based infrastructure spending, while cross-town rival Roche Holding said it would invest US$50 billion. In May, French drugmaker Sanofi announced intent to invest at least US$20 billion in the US by 2030. Pascal Soriot, who's been chief executive officer of Astra since 2012, has also urged tariff restraint. This spring, he recommended that US officials exempt medicines from tariffs, arguing that tax incentives are a better way to attract investment in drug development and manufacturing. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would be imposed as soon as Aug 1. The president said that he expects to give companies a year to bring manufacturing to the US before imposing tariffs as high as 200 per cent. Meanwhile, Soriot has raised concerns in the UK about his commitment to the home country. He has long complained about the UK's regulatory environment, which he says is a threat to hold back the UK from staying competitive with the US and China. In January, Astra abandoned plans for a £450 million (S$777 million) vaccine manufacturing plant in Liverpool. The company operates 17 manufacturing sites in 12 US states. Earlier this month, British paper The Times reported that Soriot is considering moving the company's stock listing to the US. That would be a major blow to the UK's equity markets, which have endured similar defections from other companies in recent years. Under Soriot's leadership, Astra's market value has more than tripled as the company has become a global powerhouse in cancer medicines. It's also built up a significant drug pipeline for other areas including cardiovascular, renal and metabolic diseases. BLOOMBERG
